| Jeremy Waldman, MD | |
|
17 Riverside St, Suite 105, Nashua, NH 03062-1304 | |
| (603) 577-5559 | |
| (603) 577-5579 |
| Full Name | Jeremy Waldman |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 23 Years |
| Location | 17 Riverside St, Nashua, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437129665 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 13475 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Hospital | Nashua, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Waldman Plastic Surgery And Dermatology, Pllc | 7618061300 | 4 |
News Archive
Scientists have known for decades that the Hox family of transcription factors are key regulators in the formation of blood cells and the development of leukemia.
Carmenta Bioscience, Inc., a privately held medical technology company focused on maternal and fetal health, today announced it has acquired the option for a worldwide, exclusive license from Stanford University to develop a set of tests enabling physicians to better diagnose and predict preeclampsia.
Optimer Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Optimer reported a net loss for the third quarter of 2010 of $11.8 million, or $0.30 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share. The increase in net loss was primarily due to an increase in research and development and marketing expenses.
An international study showed testosterone, when used with no other hormone therapy, is an effective treatment for low libido in postmenopausal women.
› Verified 7 days ago
| Entity Name | Waldman Plastic Surgery And Dermatology, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376736330 PECOS PAC ID: 7618061300 Enrollment ID: O20070926000387 |
News Archive
Scientists have known for decades that the Hox family of transcription factors are key regulators in the formation of blood cells and the development of leukemia.
Carmenta Bioscience, Inc., a privately held medical technology company focused on maternal and fetal health, today announced it has acquired the option for a worldwide, exclusive license from Stanford University to develop a set of tests enabling physicians to better diagnose and predict preeclampsia.
Optimer Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Optimer reported a net loss for the third quarter of 2010 of $11.8 million, or $0.30 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share. The increase in net loss was primarily due to an increase in research and development and marketing expenses.
An international study showed testosterone, when used with no other hormone therapy, is an effective treatment for low libido in postmenopausal women.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeremy Waldman, MD 17 Riverside St, Suite 105, Nashua, NH 03062-1304 Ph: (603) 577-5559 | Jeremy Waldman, MD 17 Riverside St, Suite 105, Nashua, NH 03062-1304 Ph: (603) 577-5559 |
News Archive
Scientists have known for decades that the Hox family of transcription factors are key regulators in the formation of blood cells and the development of leukemia.
Carmenta Bioscience, Inc., a privately held medical technology company focused on maternal and fetal health, today announced it has acquired the option for a worldwide, exclusive license from Stanford University to develop a set of tests enabling physicians to better diagnose and predict preeclampsia.
Optimer Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Optimer reported a net loss for the third quarter of 2010 of $11.8 million, or $0.30 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share. The increase in net loss was primarily due to an increase in research and development and marketing expenses.
An international study showed testosterone, when used with no other hormone therapy, is an effective treatment for low libido in postmenopausal women.
› Verified 7 days ago
Mark Barbour Constantian, M.D. Plastic Surgery Medicare: Medicare Enrolled Practice Location: 19 Tyler St, Suite 302, Nashua, NH 03060 Phone: 603-880-7700 Fax: 603-880-6660 | |
Donna J. Mayo, L.P.N. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 19 Tyler St, Suite 302, Nashua, NH 03060 Phone: 603-880-7700 Fax: 603-880-6660 |